Intelligence Feed event · Policy · 2026-09-19

    Teva Real-World Study Shows UZEDY Outperforms Long-Acting Injectables

    Question

    Teva Real-World Study Shows UZEDY Outperforms Long-Acting Injectables

    Direct answer

    Teva Pharmaceutical presented real-world evidence confirming that UZEDY (risperidone) extended-release injectable suspension achieved superior treatment continuity relative to other long-acting injectables in schizophrenia, as well as oral options in bipolar I disorder. The dataset revealed lower emergency care utilization and aggregate hospital costs among patients maintained on UZEDY. Concurrently, discrete choice findings showed high practitioner alignment with AUSTEDO for tardive dyskinesia management.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-19
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Teva Real-World Study Shows UZEDY Outperforms Long-Acting Injectables”, revision 1, evidence through 2026-09-19. https://marketontology.com/market-events/2026-09-19/teva-real-world-study-shows-uzedy-outperforms-long-acting-injectables-73dfce

    POLICY
    Teva Real-World Study Shows UZEDY Outperforms Long-Acting Injectables
    Teva Pharmaceutical presented real-world evidence confirming that UZEDY (risperidone) extended-release injectable suspension achieved superior treatment continuity relative to other long-acting injectables in schizophrenia, as well as oral options in bipolar I disorder. The dataset revealed lower emergency care utilization and aggregate hospital costs among patients maintained on UZEDY. Concurrently, discrete choice findings showed high practitioner alignment with AUSTEDO for tardive dyskinesia management.
    TEVA
    Impact
    60
    SEP 19
    SIG
    82%
    TEVA
    Teva Real-World Study Shows UZEDY Outperforms Long-Acting Injectables
    Teva Pharmaceutical presented real-world evidence confirming that UZEDY (risperidone) extended-release injectable suspension achieved superior treatment continuity relative to other long-acting injectables in schizophrenia, as well as oral options in bipolar I disorder. The dataset revealed lower emergency care utilization and aggregate hospital costs among patients maintained on UZEDY. Concurrently, discrete choice findings showed high practitioner alignment with AUSTEDO for tardive dyskinesia management.
    → Superior real-world clinical persistence expands commercial formulary tier access and supports TEVA branded specialty revenue trajectory.
    Impact
    Teva Pharmaceutical presented real-world evidence confirming that UZEDY (risperidone) extended-release injectable suspension achieved superior treatment continuity relative to other long-acting injectables in schizophrenia, as well as oral options in bipolar I disorder. The dataset revealed lower emergency care utilization and aggregate hospital costs among patients maintained on UZEDY. Concurrently, discrete choice findings showed high practitioner alignment with AUSTEDO for tardive dyskinesia management.
    Affected
    TEVA
    Transmission
    Superior real-world clinical persistence expands commercial formulary tier access and supports TEVA branded specialty revenue trajectory.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TEVAspecialty brand revenue growth via improved payer formulary placementUp1-4wReal-world study confirms treatment continuity and healthcare cost reduction for UZEDY

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month